BusinessMotilal Oswal Recommends Buying Molbio Diagnostics Despite 80% Rise
Molbio Diagnostics, a Goa-based healthcare company specializing in affordable diagnostic tests, has surged over 80% since its IPO on August 17, rising from ₹807 to ₹1,475.50 in under two months. Despite recent minor declines, Motilal Oswal Financial Services has given a buy rating with a target price implying a 20% upside, valuing the stock at 45 times forward earnings.
Mint Markets··Goa



